MedTrace Logo

DIPB vs. SIFIB for Postoperative Analgesia After Hip Surgery

NCT07452120 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-04-02

No results posted yet for this study

Summary

This randomized, double-blind clinical trial aims to compare the effectiveness of the Deep Iliacus Plane Block (DIPB) and the Suprainguinal Fascia Iliaca Block (SIFIB) for postoperative pain control in patients undergoing primary total hip arthroplasty. Effective analgesia after hip surgery is essential for early mobilization, reduction of complications, and improved recovery outcomes.

Seventy patients scheduled for elective hip arthroplasty under spinal anesthesia will be randomly assigned to receive either DIPB or SIFIB at the end of surgery. Postoperative pain scores, opioid consumption, motor block, and block-related complications will be evaluated over a 48-hour period.

The study aims to determine whether DIPB provides superior or comparable analgesia with reduced motor blockade compared to SIFIB, thereby contributing to safer and more comprehensive postoperative pain management in hip surgery patients.

Conditions

  • Hip Arthroplasty
  • Postoperative Pain
  • Regional Anesthesia
  • Acute Postoperative Pain

Interventions

PROCEDURE

Suprainguinal Fascia Iliaca Block

Ultrasound-guided suprainguinal fascia iliaca compartment block performed at the end of surgery using 0.25% bupivacaine (30-40 mL, weight-adjusted) for postoperative analgesia following primary total hip arthroplasty.

PROCEDURE

Deep Iliacus Plane Block

Ultrasound-guided deep iliacus plane block performed at the end of surgery using 0.25% bupivacaine (30-40 mL, weight-adjusted) for postoperative analgesia following primary total hip arthroplasty.

Sponsors & Collaborators

  • Sivas Numune Hospital

    lead OTHER_GOV

Principal Investigators

  • Fatih BALCI · Sivas Numune Hospital, Department of Anesthesiology and Reanimation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-27
Primary Completion
2026-10-01
Completion
2026-11-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07452120 on ClinicalTrials.gov